Adimmune Corporation
TWSE:4142.TW
22 (TWD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,785.094 | 2,251.624 | 1,641.061 | 1,869.147 | 1,299.689 | 822.366 | 562.743 | 606.725 | 290.737 | 480.506 | 414.093 | 387.162 | 290.363 | 834.775 | 1,369.929 |
| Cost of Revenue
| 1,374.159 | 1,360.542 | 1,176.916 | 1,246.085 | 1,132.1 | 1,116.673 | 823.983 | 795.369 | 581.143 | 685.7 | 661.521 | 757.535 | 519.724 | 298.349 | 344.777 |
| Gross Profit
| 410.935 | 891.082 | 464.145 | 623.062 | 167.589 | -294.307 | -261.24 | -188.644 | -290.406 | -205.194 | -247.428 | -370.373 | -229.361 | 536.426 | 1,025.152 |
| Gross Profit Ratio
| 0.23 | 0.396 | 0.283 | 0.333 | 0.129 | -0.358 | -0.464 | -0.311 | -0.999 | -0.427 | -0.598 | -0.957 | -0.79 | 0.643 | 0.748 |
| Reseach & Development Expenses
| 296.934 | 346.42 | 321.284 | 337.684 | 235.639 | 205.913 | 222.325 | 164.706 | 205.479 | 238.831 | 189.012 | 152.164 | 194.846 | 143.91 | 86.004 |
| General & Administrative Expenses
| 313.24 | 295.318 | 304.26 | 281.904 | 212.808 | 184.63 | 194.965 | 204.273 | 218.747 | 183.211 | 178.209 | 122.973 | 135.468 | 128.969 | 140.171 |
| Selling & Marketing Expenses
| 129.632 | 150.791 | 45.407 | 29.288 | 18.121 | 31.637 | 26.691 | 34.248 | 22.893 | 20.368 | 31.839 | 20.978 | 21.435 | 42.701 | 58.358 |
| SG&A
| 836.748 | 446.109 | 349.667 | 311.192 | 230.929 | 216.267 | 221.656 | 238.521 | 241.64 | 203.579 | 210.048 | 143.951 | 156.903 | 171.67 | 198.529 |
| Other Expenses
| 0 | 78.33 | 231.182 | 1,241.238 | 25.446 | 94.967 | -32.472 | -2.169 | 32.298 | 29.187 | 25.061 | 16.368 | 8.016 | 11.728 | 8.684 |
| Operating Expenses
| 1,133.682 | 792.529 | 670.951 | 648.876 | 466.568 | 422.18 | 443.981 | 403.227 | 447.119 | 442.41 | 399.06 | 296.115 | 351.749 | 315.58 | 284.533 |
| Operating Income
| -722.747 | 183.794 | 28.973 | 1,219.427 | -273.533 | -716.487 | -705.221 | -591.871 | -737.525 | -647.604 | -646.488 | -666.488 | -581.11 | 220.846 | 740.619 |
| Operating Income Ratio
| -0.405 | 0.082 | 0.018 | 0.652 | -0.21 | -0.871 | -1.253 | -0.976 | -2.537 | -1.348 | -1.561 | -1.721 | -2.001 | 0.265 | 0.541 |
| Total Other Income Expenses Net
| -47.232 | 62.649 | 68.376 | 1,223.078 | -15.613 | 50.573 | -71.75 | -35.692 | 6.455 | -11.45 | -18.311 | -7.027 | -9.513 | 6.283 | 4.468 |
| Income Before Tax
| -769.979 | 156.216 | 14.285 | 1,197.264 | -314.592 | -665.914 | -776.971 | -627.563 | -731.07 | -659.054 | -664.799 | -673.515 | -590.623 | 227.129 | 745.087 |
| Income Before Tax Ratio
| -0.431 | 0.069 | 0.009 | 0.641 | -0.242 | -0.81 | -1.381 | -1.034 | -2.515 | -1.372 | -1.605 | -1.74 | -2.034 | 0.272 | 0.544 |
| Income Tax Expense
| 0 | 10 | -14.093 | -21.819 | 7.145 | 94.967 | -49.267 | -34.38 | 51.249 | -41.013 | -64.346 | -69.835 | -119.305 | 65.822 | 156.205 |
| Net Income
| -639.891 | 146.216 | 28.378 | 1,241.246 | -321.737 | -609.117 | -760.176 | -595.352 | -761.087 | -614.422 | -600.453 | -603.68 | -471.318 | 161.307 | 588.882 |
| Net Income Ratio
| -0.358 | 0.065 | 0.017 | 0.664 | -0.248 | -0.741 | -1.351 | -0.981 | -2.618 | -1.279 | -1.45 | -1.559 | -1.623 | 0.193 | 0.43 |
| EPS
| -1.52 | 0.34 | 0.066 | 3.03 | -0.89 | -2.59 | -3.07 | -2.41 | -3.08 | -2.89 | -3.09 | -3.23 | -2.73 | 0.95 | 3.54 |
| EPS Diluted
| -1.52 | 0.34 | 0.066 | 3.03 | -0.89 | -2.59 | -3.07 | -2.41 | -3.08 | -2.89 | -3.09 | -3.23 | -2.73 | 0.95 | 3.51 |
| EBITDA
| -512.428 | 443.11 | 254.886 | 1,447.01 | -33.322 | -372.115 | -445.843 | -302.293 | -400.023 | -318.985 | -326.338 | -366.553 | -333.307 | 450.251 | 861.378 |
| EBITDA Ratio
| -0.287 | 0.197 | 0.155 | 0.774 | -0.026 | -0.442 | -0.792 | -0.498 | -1.376 | -0.664 | -0.788 | -0.946 | -1.148 | 0.539 | 0.626 |